Novabay Pharmaceuticals, INC

Stablecoin Development Corporation reported Q2 2026 results, highlighting $2.2 million in staking revenue and a significant unrealized loss on digital assets, while growing its SKY token holdings.

Stablecoin Development Corporation announced the appointment of Henry Blynn as Chief Operating Officer and set Michael Kazley's CEO salary for 2027.

Stablecoin Development Corporation amended pre-funded warrants with R01 Fund LP and Framework Ventures IV L.P., leading to the issuance of over 22.6 million shares.

Stablecoin Development Corporation reported first quarter 2026 operating income of $22.3 million and GAAP net income of $552.4 million, significantly boosted by non-cash warrant-related gains.

Stablecoin Development Corporation announced that its previously issued 2025 financial statements must be reissued due to an accounting error related to pre-funded warrants.

Stablecoin Development Corporation, formerly NovaBay Pharmaceuticals, has officially rebranded and reported holding 2.15 billion SKY tokens.

Stablecoin Development Corporation reported significant shifts in its financial statements for Q2 2026, driven by digital asset holdings and warrant liability adjustments, alongside a strategic pivot.

NovaBay Pharmaceuticals, Inc. reported a net income of $4.455 million for the nine months ended September 30, 2025, driven by divestitures, and announced a strategic pivot towards blockchain-based assets while regaining NYSE American compliance.

NovaBay Pharmaceuticals reports a net income of $5.7 million for the first half of 2025 driven by asset divestitures, as it evaluates strategic options including potential dissolution.

NovaBay Pharmaceuticals reports a net income of $7.67 million for Q1 2025, driven by gains from asset divestitures, while the company evaluates strategic options including a potential dissolution.

NovaBay Pharmaceuticals reports its Q3 2024 results, highlighting a strategic shift towards a potential asset sale and dissolution, while navigating financial challenges.

NovaBay Pharmaceuticals announced its second quarter 2024 results, highlighting the completion of the DERMAdoctor divestiture and a focus on its core eyecare and wound care segments.

Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.) is restating its 2025 financial statements due to an accounting error related to common stock warrants, impacting warrant liability by $608.6 million.

NovaBay Pharmaceuticals, Inc. has completed a significant business realignment, divesting its legacy pharmaceutical operations to focus on a blockchain-based digital asset strategy, primarily acquiring SKY tokens.

NovaBay Pharmaceuticals is evaluating strategic options, including a potential dissolution, after selling its Avenova and wound care assets.

NovaBay Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include a previously omitted exhibit, with no other changes made to the original filing.

NovaBay Pharmaceuticals outlines its non-employee director compensation plan and provides a comprehensive financial overview in its annual 10-K filing.

CEO Michael Kazley exercised pre-funded warrants for 11.3 million shares of Stablecoin Development Corp, resulting in a net increase in beneficial ownership.

Framework Ventures IV L.P. exercised pre-funded warrants to acquire 11,307,300 shares of Stablecoin Development Corp common stock.

R01 Fund LP and CEO Michael Kazley increased their stake in Stablecoin Development Corp through the exercise of pre-funded warrants.

Framework Ventures IV L.P. acquired 50,109,253 pre-funded warrants in Stablecoin Development Corp for $0.85 per warrant.

R01 Fund LP and affiliated entities have acquired 53,679,974 pre-funded warrants in Stablecoin Development Corp at $0.85 per warrant.

CEO Michael Kazley, through R01 Entities, acquired 53,679,974 pre-funded warrants of Stablecoin Development Corp at $0.85 per warrant.

NovaBay Pharmaceuticals' CEO David Lazar resigned, effective upon the transfer of his preferred stock and rights to R01 Fund LP and Framework Ventures IV L.P., who are expected to collectively own 90% of the company's common stock.

NovaBay Pharmaceuticals announces a strategic pivot with a new $6.0 million investment from David E. Lazar, leading to significant shareholder dilution and a planned reverse stock split.

NovaBay Pharmaceuticals provided important details regarding its $0.80 per share special cash dividend and announced the record and meeting dates for its 2025 Annual Meeting of Stockholders.

NovaBay Pharmaceuticals is seeking stockholder approval to dissolve the company and liquidate its assets following the sale of its Avenova and wound care assets.

NovaBay Pharmaceuticals engages Lucid Capital Markets to explore strategic alternatives, including a potential business combination, as it faces uncertainty regarding stockholder approval for the company's proposed liquidation and dissolution.

NovaBay Pharmaceuticals' stockholders did not approve the proposed liquidation and dissolution plan at a special meeting, prompting the company to schedule another vote.

NovaBay Pharmaceuticals aims to raise approximately $3.16 million through a public offering of common stock and warrants to fund working capital and general corporate purposes.

NovaBay Pharmaceuticals aims to raise capital through a public offering of common stock and warrants to support its eyecare and wound care product lines, including Avenova Spray.

NovaBay Pharmaceuticals is launching a public offering of common stock, pre-funded warrants, and accompanying Series F-1 and F-2 warrants to raise capital for working capital and general corporate purposes.

NovaBay Pharmaceuticals is seeking to raise capital through a public offering of common stock and warrants to fund its eyecare and wound care product lines, including its flagship Avenova Spray.

NovaBay Pharmaceuticals is registering the resale of up to 298,355 shares of its common stock by selling stockholders, issuable upon the exercise of warrants and conversion of unsecured convertible notes.

Framework Ventures IV L.P. and associated entities have increased their beneficial ownership in Stablecoin Development Corp to 46.7% following the vesting of pre-funded warrants.

R01 Fund LP and associated entities have increased their beneficial ownership in Stablecoin Development Corp to 48.4% following the vesting of pre-funded warrants.

Sky Frontier Foundation updates its Schedule 13D filing to reflect a change in beneficial ownership percentage due to an increase in Stablecoin Development Corp's outstanding shares.

Framework Ventures IV L.P. has increased its beneficial ownership in Stablecoin Development Corp to 45.9% following the full cashless exercise of pre-funded warrants.

R01 Fund LP and associated entities have increased their beneficial ownership in Stablecoin Development Corp to 49.8% following a full cashless exercise of pre-funded warrants.

Sky Frontier Foundation has acquired a pre-funded warrant for 100,000,000 shares of Stablecoin Development Corp, representing a 9.99% beneficial ownership.

Tether Global Investments Fund and Giancarlo Devasini have filed a Schedule 13G disclosing a 9.99% beneficial ownership stake in Stablecoin Development Corp.

Poplar Point Capital Management and its affiliates have disclosed a significant 16.71% beneficial ownership stake in NovaBay Pharmaceuticals, Inc., holding 971,654 shares of common stock.

Poplar Point Capital Management LLC and its affiliates have disclosed a 12.7% passive beneficial ownership stake in NovaBay Pharmaceuticals, Inc., as reported in an amended Schedule 13G filing.

Poplar Point Capital Management LLC and its affiliates have disclosed a passive beneficial ownership of 7.7% in NovaBay Pharmaceuticals, Inc. common stock.